

PATENT  
ATTORNEY DOCKET NO. 044137-5025-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Continued Prosecution Application of:	)	
	)	
Alan SOLOMON <i>et al.</i>	)	
	)	
Application No.: 09/316,387	)	Group Art Unit: 1647
	)	
Filed: May 21, 1999	)	Examiner: S. Turner
	)	
For: METHODS FOR AMYLOID REMOVAL	)	
USING ANTI-AYLOID ANTIBODIES	)	

Commissioner for Patents  
U.S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

Sir:

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents were submitted with the response filed on October 23, 2002 and therefore are not attached here. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents do not

**RECEIVED**  
JUN 30 2003  
TECH CENTER 1600/2900


constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

**Except** for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully submitted,

**MORGAN, LEWIS & BOCKIUS LLP**

  
Sally P. Teng  
Reg. No. 45,397

Dated: June 27, 2003

**Customer No. 09629**  
**MORGAN, LEWIS & BOCKIUS LLP**  
1111 Pennsylvania Avenue, N.S.  
Washington, D.C. 20004  
(202) 739-3000

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
Patent and Trademark Office

Atty. Dkt. No.

Client/Matter No.

Client Ref.

044137-5025-01

JUN 27 2003

Applicant: Alan SOLOMON et al.

Appln. No.: 09/316,387

Filing Date: May 21, 1999

Date: Page 1 of 1

Examiner: S. Turner

Group Art Unit: 1647

# U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						
CR						
DR						
ER						

# FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							Abstract		Readily Available	
		Document Number	Date MM/YYYY	Country	Inventor Name		Enclosed	No	Enclose	No
	FR									
	GR									
	HR									
	IR									
	JR									

# OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

KR	Holmgren et al., Lancet, Vol. 341, May 1, 1993, pp. 1113-1116				
LR	Kuo et al., "Water-soluble A $\beta$ (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains", The Journal of Biological Chemistry, Vol. 271, No. 8, Feb. 23, 1996, pp. 4077-4081				
MR	Schehr, "Therapeutic Approaches to Alzheimer's Disease", Bio/Technology, Vol. 12, Feb. 1994, pp. 140-144				
NR	Grubeck-Loebenstien et al., "Immunization with $\beta$ -amyloid: could T-cell activation have a harmful effect?", TINS, Vol. 23, No. 3, 2000, pp. 11				
OR	Lee, "A $\beta$ immunization: Moving A $\beta$ peptide from brain to blood", PNAS, Vol. 98, No. 16, July 31, 2001, pp. 8931-8932				
PR	Shenk et al., "Immunization with amyloid- $\beta$ attenuates Alzheimer-disease-like pathology in the PDAPP mouse", Nature, Vol. 400, July 8, 1999, pp. 173-177				
QR	Falk et al., "The Systemic Amyloidoses", The New England Journal of Medicine, Vol. 337, No. 13, Sept. 25, 1997, pp. 898-908				
RR	Tjernberg et al., "Arrest of $\beta$ -Amyloid Fibril Formation by a Pentapeptide Ligand", The Journal of Biological Chemistry, Vol. 271, No. 15, April 12, 1996, pp. 8545-8548				
SR	Kisilevsky, "Anti-Amyloid Drugs - Potential in the Treatment of Diseases Associated with Aging", Drugs & Aging, Vol. 8, No. 2, Feb., 1996, pp. 75-83				
TR					

Examiner

Date Considered:

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.